Another EU vaccine failure as Germany's CureVac jab is found to only have 47% efficacy

The results from a trial with 40,000 participants have caused CureVac shares in Frankfurt and New York to fall more than 50 per cent, erasing more than £5billion from the company's market value.

from Articles | Mail Online https://ift.tt/3wwzEd0